Phenomics and Genomics of Clozapine Pharmacotherapy (CLOZIN)

• ClinicalTrials.gov Identifier: NCT03253367
• Recruitment Status: Unknown
• First Posted: August 17, 2017
• Last Update Posted: March 5, 2020
• Sponsor: Jurjen Luykx
• Information provided by (Responsible Party): Jurjen Luykx, UMC Utrecht

Study Description

Brief Summary:

A burgeoning body of research has pointed to increased efficacy of clozapine (CLZ) over other antipsychotics in schizophrenia (SCZ). On the other hand, safety concerns likely cause underutilization across a range of European and other nations. The lack of data available to predict efficacy and adverse drug reactions (ADRs) of CLZ further contributes to underprescription rates in these countries. Here, we hypothesize that (epi)genetic and non-genetic factors aid to help predict treatment outcome (efficacy + ADRs) to CLZ. We furthermore posit that such prediction will result in enhanced quality of life of both patients and family members. Our primary objective is to predict CLZ treatment outcome based on phenotypic and genetic data obtained through the current design. The first secondary objective is to investigate which methylation levels/patterns are correlated with CLZ treatment outcome. The second secondary objective is to aid in the further elucidation of the genetic architecture of SCZ and any possible differences between 'regular' SCZ patients and those on CLZ, who are generally more severely ill. We thus intend to cover two currently unmet needs using a precision medicine approach: the lack of knowledge about determinants of treatment response to CLZ and the lack of insight into neurobiological differences between 'regular' SCZ and relatively treatment resistant subjects (CLZ users). The prime analysis will be a common variant hypothesis-generating genotyping endeavor investigating treatment response to CLZ. Additional analyses include whole-genome methylation and gene expression analyses and analyses of non-genetic determinants of response. We will include 2,500 CLZ treated patients for our discovery cohort, which is in line with previous whole-genome pharmacogenomics studies and our power calculations. We will replicate any genome-wide loci using our prospectively collected cohort of new users (N=59). Potential yields include a publicly available prediction tool to help identify patients responsive to CLZ in early disease stages and prevent harmful effects. In addition, common variant analyses compounded by pathway analyses may help elucidate the mechanisms of action of CLZ. We ask for broad informed consent from participants ensuring rich, longitudinal phenotypic and genotypic data resources for both currently planned and future analyses, allowing e.g. next-generation sequencing focused on both CLZ and SCZ disease genetics (e.g. in large consortia). We plan to also generate polygenic risk scores (PRS) of CLZ efficacy and use those to identify other diseases or patients for which CLZ may be helpful, e.g. schizoaffective disorder patients who are sometimes first treated with mood stabilizers. Last, evidence hints that disparaging genetic loci influence efficacy to different antipsychotics. Adding genetic data from our cohort to existing datasets of response to other antipsychotics may help identify such loci. Finally, comparison studies with non-CLZ using patients suffering from SCZ may deepen the understanding of biological mechanisms underlying treatment resistance (or: a relatively severe course of illness).The results of this genetic part of the study will be combined with the results from our other research protocol 'Phenomics and genomic of clozapine pharmacotherapy - New Users'.The overarching goal of both projects is to create a prediction model for clozapine outcome (response (and side effects). This model includes genetic, epigenetic and clinical data.

Condition or disease	Intervention/treatment
Schizophrenia Spectrum and Other Psychotic Disorders	Other: Blood is obtained, mostly during routine venipuncture

Detailed Description:

Rationale Clozapine (CLZ) is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement, thereby implying that patients on CLZ generally suffer from more severe and/or persistent symptoms than patients suffering from schizophrenia spectrum disorders (SCZ) on other antipsychotic agents. Unraveling the (functional) genetic variation underlying this severe SCZ phenotype therefore has the potential to deepen our understanding of the biological underpinnings of SCZ beyond the boundaries of DSM-based consensus criteria. Such knowledge in turn has the potential to shape future pharmacotherapeutic research. The investigators here hypothesize that targeting this phenotype in genome-wide association studies and next-generation sequencing studies will signal genetic risk loci implicated in this severe SCZ phenotype. In the future, this may lead to early detection of severe SCZ, which in turn will enable tailoring of pharmacotherapeutic strategies to such SCZ subtypes. The results of this genetic part of the study will be combined with the results from our other research protocol ('Phenomics and genomic of clozapine pharmacotherapy - New Users').The overarching goal of both projects is to create a prediction model for clozapine outcome (response (and side effects). This model includes genetic, epigenetic and clinical data.

Objectives

Primary:

1) To predict CLZ efficacy and ADRs (=treatment outcome) based on phenotypic and genetic data obtained in this study.

Secondary:

1. To investigate which non-genetic factors, methylation and gene expression levels/patterns predict treatment outcome after initiating CLZ;
2. As the genetic architecture of SCZ has not been fully elucidated, the current project will aid in the further elucidation of the genetic architecture of SCZ and any possible differences between 'regular' SCZ patients (those not considered treatment resistant) and those on CLZ (considered generally to be a more homogeneous and severe group).

Study design This is a mostly cross-sectional study, in which both phenotypic and genotypic data are gathered from this study population that currently uses CLZ or has used CLZ in the past. A genome-wide association study (GWAS) will be performed to reveal possible differences in genetic architecture between patients who use or have used CLZ and the broad schizophrenia phenotype on the one hand and between those who use or have used CLZ and healthy controls on the other. Targeted next-generation sequencing may be used to follow-up possible positive associations. The genetic data will be used to analyse which genetic variants are associated with CLZ response and/or side effects.

Study population The investigators will include 2,500 patients diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS (together referred to as SCZ) >18 years of age who are currently on CLZ treatment or have used CLZ in the past. Publicly available Psychiatric Genomics Consortium (PGC) GWAS data will be used for comparisons with the broad schizophrenia phenotype group. For the purpose of the case-control comparison, the 2,500 subjects who use or have used CLZ will be age and sex-matched to 30,000 healthy control subjects for whom genotype data are available in-house.

Intervention No intervention will be applied.

Main study parameters/endpoints

1. To assess whether the genetic architecture of this severe SCZ phenotype differs from the broad DSM-based SCZ phenotype.
2. To predict clozapine response and side effects based on phenotypic and genetic data obtained in this study.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness Almost all patients on CLZ regularly have their blood drawn for routine white blood cell counts and/or CLZ blood level assessments. The investigators anticipate that the majority of the study population will consist of such patients as white blood cell monitoring is strictly enforced in clinical practice for this patient group. For these patients, no additional risks will be attached to the study, as the blood necessary for DNA extraction for the current study will be drawn during these routinely performed venipunctures. Time investment will also be low as the patients will only undergo a 10-minute interview. A minority of patients on CLZ does not have their blood routinely monitored and neither do patients who have used CLZ in the past. These subjects will be asked to allow a single blood draw. A venipuncture entails the risk of a hematoma (blood leaving the vessel). The investigators aim to minimize this risk by only allowing experienced personnel to draw blood and in the event of deeply located or thin veins request central lab personnel to perform the venipuncture. Although a hematoma resulting from a traumatic puncture imposes an esthetical burden on the subject, no serious health risks are involved.

Study Design

• Study Type: Observational
• Estimated Enrollment: 2500 participants
• Observational Model: Cohort
• Time Perspective: Other
• Official Title: Phenomics and Genomics in Clozapine Pharmacotherapy: Current, Former and New Clozapine Users
• Actual Study Start Date: January 19, 2016
• Estimated Primary Completion Date: December 2021
• Estimated Study Completion Date: December 2021

Groups and Cohorts

Group/Cohort	Intervention/treatment
Current/former clozapine users; This group has only one visit.	Other: Blood is obtained, mostly during routine venipuncture
New clozapine users; This group will be followed for 6 months prospectively.	Other: Blood is obtained, mostly during routine venipuncture

Outcome Measures

Primary Outcome Measures :

1. Predict clozapine response. [ Time Frame: 2016-2021 ]
   To predict clozapine response based on phenotypic information from our questionnaire (CGI + CRES) and genetic information from GWAS
2. Predict side effects from clozapine use [ Time Frame: 2016-2021 ]
   To predict clozapine response based on phenotypic information from our questionnaire (LUNSERS) and genetic information from GWAS
3. Assess differences in genetic architecture (GWAS) [ Time Frame: 2016-2021 ]
   To assess whether the genetic architecture of this severe SCZ phenotype differs from the broad DSM-based SCZ phenotype. this will be done by comparing the gentic material of clozapine users vs. non-clozapine users. Only the clozapine DNA has to be collected yet.

Secondary Outcome Measures :

1. Detect genetic associations (GWAS) Detect genetic associations current severe SCZ phenotype [ Time Frame: 2016-2021 ]
   To detect genetic associations with the current severe SCZ phenotype by performing a case-control comparison with healthy participants (GWAS).
2. Increase or decrease cardiovascular disease? [ Time Frame: 2016-2031 ]
   To investigate whether CLZ use increases or decreases the risk of cardiovascular disease and early death. This is done by following the patients for 10 years and see whether they developed serious cardiovascular diseases

Biospecimen Retention:   Samples With DNA

For current and former users we obtain DNA and for new users we also obtain RNA

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

The investigators will include 2,500 patients diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS (together referred to as SCZ) >18 years of age who are currently on CLZ treatment or have used CLZ in the past. Publicly available Psychiatric Genomics Consortium (PGC) GWAS data will be used for comparisons with the broad schizophrenia phenotype group. For the purpose of the case-control comparison, the 2,500 subjects who use or have used CLZ will be age and sex-matched to 13,000 healthy control subjects for whom genotype data are available in-house.

Criteria

Inclusion Criteria:

• he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ
• he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS.
• his/her age must be ≥18 years old
• he/she must be able to speak and read the language of the Informed Consent (differs per country)
• he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study

Exclusion Criteria:

• admission to a psychiatric unit involuntarily (not all countries)
• a history of Parkinson's disease

Contacts and Locations

Contacts

Contact: Marte van der Horst, Drs.; 0887551460 ext +31; mzvanderhorst@gmail.com

Contact: Jurjen Luykx, PhD; 0887568638 ext +31; j.luykx@umcutrecht.nl

Locations

Austria

Medical University Innsbruck; Recruiting

Innsbruck, Austria, 6020

Contact: Monika Edlinger, MD monika.edlinger@i-med.ac.at

Finland

Niuvanniemen hospital; Recruiting

Kuopio, Finland, 70240

Contact: Jari Tiihonen, Prof.

Germany

LMU Munich; Recruiting

München, Munich, Germany, 80336

Contact: Alkomiet Hasan, MD, PhD

Charité Universitätsmedizin Berlin; Recruiting

Berlin, Germany, 10117

Contact: Stefanie Schreiter, MD 004930450517009 stefanie.schreiter@charite.de

Contact: Stefan Gutwinski, MD 004930450517009 stefan.gutwinski@charite.de

Netherlands

Vincent van Gogh Institute; Withdrawn

Venray, Limburg, Netherlands, 5803 AC

Reinier van Arkel; Recruiting

's-Hertogenbosch, Noord-Brabant, Netherlands, 5211 LJ

Contact: Koen Grootens, MD

GGZ-NHN; Terminated

Heerhugowaard, Noord-Holland, Netherlands, 1703 WC

GGZ Rivierduinen; Enrolling by invitation

Leiden, Oegstgeest, Netherlands, 2342 EJ

Yulius; Terminated

Barendrecht, Zuid Holland, Netherlands, 2994 GC

UMC Utrecht; Recruiting

Utrecht, Netherlands, 3508 GA

Contact: Marte van der Horst, Drs. 0887551460 ext +31 c.pfeifer@umcutrecht.nl

Altrecht; Terminated

Utrecht, Netherlands, 3512 PK

Sponsors and Collaborators

Jurjen Luykx

More Information

Additional Information:

Website CLOZIN study 

• Responsible Party: Jurjen Luykx, Sponsor, UMC Utrecht
• ClinicalTrials.gov Identifier: NCT03253367
• Other Study ID Numbers: ABR: 52726 & 52728
• First Posted: August 17, 2017
• Last Update Posted: March 5, 2020
• Last Verified: March 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Anonymous data can be shared with other investigators when the sponsor agreed on the workpackage of that investigator.

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jurjen Luykx, UMC Utrecht:

Schizophrenia Spectrum and Other Psychotic Disorders

Additional relevant MeSH terms:

Schizophrenia; Mental Disorders; Psychotic Disorders; Schizophrenia Spectrum and Other Psychotic Disorders